is a preclinical stage company developing novel immunotherapies to treat cancer. To address unmet medical needs, is developing its proprietary platform effective against both hematological cancers and solid tumors regardless of the type of previous treatments patients have experienced.

The use of human T cells as therapeutics and the administration of anti-checkpoints are revolutionizing the way cancer is treated. We believe investments in research capabilities including access to state-of-the-art gene transfer and nucleotide-based technologies, will help accelerate the development of new and better options for immune-oncology therapeutics